Advanced radiotherapy for prostate cancer to cut sessions from 20 to five
Summary
Thousands of men in England with low- or intermediate-risk prostate cancer will be offered a new type of precise radiotherapy called SABR. This treatment reduces the number of sessions from 20 to five, aiming to target the cancer more effectively with fewer side effects.Key Facts
- SABR stands for stereotactic ablative radiotherapy and delivers a focused, high-powered radiation beam.
- The treatment is already used for some lung and brain cancers but is now available for certain prostate cancer patients outside of trials.
- About 17,500 men diagnosed yearly in England have low- or intermediate-risk prostate cancer; around 3,500 are expected to choose SABR.
- SABR cuts the number of radiotherapy sessions from 20 to five, helping patients recover faster.
- The NHS expects all 48 radiotherapy centers in England to offer SABR within weeks.
- Side effects are often reduced because SABR limits damage to healthy cells around the tumor.
- Trials are ongoing to see if SABR can help patients with high-risk prostate cancer.
- Patients like Edwin Lambert report fewer severe side effects and a quicker return to normal activities after SABR.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.